-
-
-
-
-
-
-
IN8bio Inc. (INAB) PT Lowered to $6 at H.C. Wainwright
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on IN8bio Inc. (INAB)
-
-
-
-
-
-
-
IN8bio, Inc (INAB) reports positive clinical data from Phase 1 trials of INB-100 for hematological malignancies and INB-200 for GBM
-
-
-
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

